For the half-year ended in the second quarter of FY March 2027, consolidated net sales were 57,489 million yen, operating income was 306 million yen, and net loss attributable to owners of the parent for the half-year was 1,566 million yen. The full-year forecast was revised from net sales 121,800 million yen to 126,257 million yen, and net income from -5,100 million yen to -6,600 million yen. The revisions reflect the transfer of the generics business and the impact of new drug development costs. Dividends have not been announced. The financial position remains stable with a equity ratio of 73.9%.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"price_fetched_at":"","company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"4569","jir_company_name":"KYORIN Pharmaceutical Co., Ltd.","jir_importance":"\u2605\u2605\u2605\u2605\u2606","jir_publication_date":"2026-11-09","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/11\/4569-20261109-01.pdf","jir_short_summary":"For the half-year ended in the second quarter of FY March 2027, consolidated net sales were 57,489 million yen, operating income was 306 million yen, and net loss attributable to owners of the parent for the half-year was 1,566 million yen. The full-year forecast was revised from net sales 121,800 million yen to 126,257 million yen, and net income from -5,100 million yen to -6,600 million yen. The revisions reflect the transfer of the generics business and the impact of new drug development costs. Dividends have not been announced. The financial position remains stable with a equity ratio of 73.9%.","jir_summary":"### Overview of Results\nUnder Vision 110 \u2013Stage2\u2013, KYORIN Pharmaceutical reported half-year net sales of 57,489 million yen, operating income of 306 million yen, ordinary income of 689 million yen, and a half-year net loss attributable to owners of the parent of -1,566 million yen. Despite stable sales of core products such as Beova in a challenging domestic prescription pharmaceutical market affected by drug price revisions, overall profitability contracted significantly due to the drug price revisions and entry of generics. A special loss related to the transfer of the generics business was also recorded. Research and development expenses decreased year-on-year. Meanwhile, the financial position remains strong with an equity ratio maintained at 73.9%.\n\n### Outlook and Key Points\nThe full-year forecast has been revised from the previously announced figures to net sales of 126,257 million yen, operating income of -6,900 million yen, ordinary income of -6,900 million yen, and net loss attributable to owners of the parent of -6,600 million yen. Revisions to profit forecasts reflect recognition of upfront payments from contracts and the inclusion of special losses. The transfer of the generics business during the half-year and new license agreements may affect the future revenue structure.","jir_financial_highlights":"Net Sales: 57,489 (Year-over-Year -2.1%)\nOperating Income: 306 (Year-over-Year -77.6%)\nOrdinary Income: 689 (Year-over-Year -56.4%)\nNet Income Attributable to Owners of Parent (Half-year): -1,566 (Year-over-Year N\/A)\nEquity Ratio: 73.9 (Prior Period +1.0 percentage points)\nFull-year Net Sales Forecast: 126,257 (From Previous Forecast +4,457)","jir_category":"","jir_hashtags":"#KYORINPharmaceutical, #Earnings, #HalfYear, #Vision110, #Stage2","jir_key_figures":"Net Sales: 57,489 million yen (Year-over-Year -2.1%)\nOperating Income: 306 million yen (Year-over-Year -77.6%)\nNet Income Attributable to Owners of Parent (Half-year): -1,566 million yen","jir_meta_title":"KYORIN Pharmaceutical \u2014 Financial Summary FY Mar 2027 Q2 | Net Sales 57,489 million yen, Operating Income 306 million yen","jir_meta_description":"","jir_og_title":"KYORIN Pharmaceutical | Financial Summary FY March 2027 Q2","jir_og_description":"Half-year financial overview of KYORIN Pharmaceutical. Analysis of net sales and profit trends, revisions to the full-year forecast, and developments in the generics business.","jir_og_image_url":"\/assets\/og\/company-financial_summary.jpg","jir_chart_data_collection":"[]","ir_related_company":16660,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"financial_summary","footnotes":""},"sector":[],"importance":[],"class_list":["post-145540","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n